This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Trillium Therapeutics Inc.. Active years: 2018-2021.
Company Filing History:
Years Active: 2018-2021
Title: Innovations of Inventor Xinli Pang
Introduction
Xinli Pang is a notable inventor based in Brampton, Canada. He has made significant contributions to the field of medical research, particularly in the treatment of cancer. With a total of 2 patents, his work focuses on innovative therapies that target specific disease cells.
Latest Patents
Pang's latest patents include groundbreaking methods for treating CD47+ disease cells using SIRPα-Fc fusions. This innovative approach involves the use of a human SIRPα fusion protein that effectively blocks signaling via the SIRPα/CD47 axis. The fusion protein is designed to have negligible CD47 agonism and minimal binding to red blood cells. It comprises an IgV domain from variant 2 of human SIRPα, along with an Fc that possesses effector function. Notably, the IgV domain binds human CD47 with an affinity that is at least five times greater than that of the entire extracellular region of human SIRPα. This fusion protein demonstrates at least five times more potency compared to counterparts lacking effector function.
Career Highlights
Xinli Pang is currently associated with Trillium Therapeutics Inc., where he continues to advance his research and innovations. His work is pivotal in developing therapies that could potentially transform cancer treatment.
Collaborations
Pang collaborates with esteemed colleagues, including Robert Adam Uger and Penka Slavtcheva Slavova-Petrova, who contribute to his research endeavors.
Conclusion
Xinli Pang's innovative work in the treatment of CD47+ disease cells showcases his commitment to advancing medical science. His contributions have the potential to significantly impact cancer therapies and improve patient outcomes.